TY  - JOUR
AU  - Weller, Michael
AU  - Le Rhun, Emilie
AU  - Van den Bent, Martin
AU  - Chang, Susan M
AU  - Cloughesy, Timothy F
AU  - Goldbrunner, Roland
AU  - Hong, Yong-Kil
AU  - Jalali, Rakesh
AU  - Jenkinson, Michael D
AU  - Minniti, Giuseppe
AU  - Nagane, Motoo
AU  - Razis, Evangelia
AU  - Roth, Patrick
AU  - Rudà, Roberta
AU  - Tabatabai, Ghazaleh
AU  - Wen, Patrick Y
AU  - Short, Susan C
AU  - Preusser, Matthias
TI  - Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.
JO  - Neuro-Oncology
VL  - 25
IS  - 7
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2023-00411
SP  - 1200–1224
PY  - 2023
AB  - Central nervous system (CNS) tumor patients commonly undergo multimodality treatment in the course of their disease. Adverse effects and complications from these interventions have not been systematically studied, but pose significant challenges in clinical practice and impact function and quality of life, especially in the management of long-term brain tumor survivors. Here the European Association of Neuro-Oncology (EANO) has developed recommendations to prevent, diagnose and manage adverse effects and complications in the adult primary brain CNS tumor (except lymphomas) patient population with a specific focus on surgery, radiotherapy and pharmacotherapy. Specifically, we also provide recommendations for dose adaptations, interruptions and re-exposure for pharmacotherapy that may serve as a reference for the management of standard of care in clinical trials. We also summarize which interventions are unnecessary, inactive or contraindicated. This consensus paper should serve as a reference for the conduct of standard therapy within and outside of clinical trials.
KW  - Adverse affects (Other)
KW  - Dose (Other)
KW  - Interruptions (Other)
KW  - Prevention (Other)
KW  - Re-exposure (Other)
KW  - Toxicity (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36843451
DO  - DOI:10.1093/neuonc/noad038
UR  - https://inrepo02.dkfz.de/record/272838
ER  -